EBC 46

Drug Profile

EBC 46

Alternative Names: EBC-46

Latest Information Update: 25 Jan 2017

Price : $50

At a glance

  • Originator QBiotics
  • Class Antineoplastics; Diterpenes; Esters; Small molecules
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 29 Nov 2016 Pharmacodynamics data from a preclinical study in Solid tumours presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2016)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in Australia (Topical, Gel)
  • 06 Nov 2014 Qbiotics plans a phase I extension trial for Solid tumours (Late-stage disease, Second--line therapy or greater) in Australia (ACTRN12614001207606)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top